C&G Editor in Chief, Erin Harris

  1. Part 2: Adaptimmune’s Deep Dive into Manufacturing & Process Development

    In Part 1 of our two-part series with Adaptimmune, CEO James Noble, who has announced his retirement since the publication of this article, provided thoughtful insight on the status of combatting solid tumors as well as the ongoing pricing issue affecting the cell and gene therapy sector. Here in Part 2, along with John Lunger, SVP, Manufacturing and Supply Chain, and Mark Dudley, SVP, Product Development at Adaptimmune, we dig deeper into the topics discussed in Part 1 — we shed granular light on how pricing will affect manufacturing; we talk outsourced versus in-house manufacturing and more. 

  2. Orchard Therapeutics Tackles ADA-SCID, MLD, And Much More

    On the heels of our sister print publication, Life Science Leader’s cover story on the whirlwind rise of Orchard Therapeutics, I had the opportunity to talk to company’s Co-Founder and Chief Scientific Officer, Dr. Bobby Gaspar about how the company has developed innovative gene therapies to treat CNS diseases, such as metachromatic leukodystrophy (MLD), tackle ADA-SCID, and more.

  3. Expected Outcomes Of Minovia Tx’s MAT Clinical Trial

    Minovia Therapeutics recently announced dosing of the first patient in a Phase I/II clinical trial of the company’s Mitochondrial Augmentation Therapy (MAT) for the treatment of Pearson syndrome. As stem cell transplantations and cellular therapies continue to gain momentum rapidly, this is an example of trial that could pave the way for the development of treatments for all mitochondrial diseases.

  4. Breaking Down Pricing Of Cell & Gene Therapies

    Erin Harris, Editor-In-Chief, Cell & Gene conferred with several SMEs in the cell and gene sector to get their take on the challenges for both industry and patient associated with cell and gene therapy prices, and what can be done, realistically, to bring costs down over time.

  5. Adaptimmune’s CEO On Pricing And Next-Gen Immuno-Oncology

    James Noble, CEO of Adaptimmune, explains where the industry is with attacking solid tumors and sheds light on the ever-present pricing issue.

  6. Cell & Gene Appoints New EAB Member

    Cell & Gene is committed to judiciously developing our best-in-class Editorial Advisory Board (EAB). Cell & Gene’s EAB is diverse and interactive, and members hail from both industry and academia. We’re pleased and honored to announce our newest member of Cell & Gene’s Editorial Advisory Board — Vijay Chiruvolu, SVP of Global Process Development, Cell Therapy at Kite Pharma.

  7. Dr. Aaron Levine On FDA’s Statement About Dubious Stem Cell Clinics

    Last month, the FDA released a statement by former FDA Commissioner Scott Gottlieb, M.D., and Biologics Center Director Peter Marks, M.D., Ph.D. on FDA’s continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk. I caught up with Dr. Aaron Levine, Associate Professor, School of Public Policy, Georgia Institute of Technology to get his take on the statement and how dubious players affect the good of the cell and gene sector.         

  8. Why Is Indication Crowding A Concern?

    Just recently, I interviewed Dr. Reni Benjamin, Managing Director, Biotechnology Equity Research at Raymond James & Associates about the panel he moderated at ARM’s 2019 Cell & Gene Therapy Investor Day. In the article, Dr. Benjamin explained how investors are thinking about the cell and gene therapy space in 2019.

  9. Attending ASGCT’s 22nd Annual Meeting?

    The ASGCT 22nd Annual Meeting will begin on the morning of Monday, April 29, 2019 and continue through 12:15 PM on Thursday, May 2, 2019. Exhibits will be open Monday, April 29 through Wednesday, May 1.

  10. What Investors Want: 7 Key Components To Raising Capital

    ARM’s 2019 Cell & Gene Therapy Investor Day featured expert-led panels to help the audience wrap their minds around the investment outlook for the cell and gene therapy space. One such panel, aptly titled, “The Investment Outlook for the Cell and Gene Space,” was comprised of investors from DEFTA Partners, Roivant Sciences, Aisling Capital, and Aquilo Capital Management. Dr. Reni Benjamin, Managing Director, Biotechnology Equity Research at Raymond James & Associates moderated the panel.